Cushings Syndrome Market Size by 2018 Opportunities | Vendors | Drivers| Challenges | Developments | Forecast


Cushing’s syndrome is a collection of symptoms and signs, which includes high blood pressure, reddish stretch marks, abdominal obesity, round red face, weak muscles, weak bones, a fat lump between the shoulders and fragile skin that heals slowly due to prolonged exposure to cortisol. Excessive cortisol-like medication such as prednisone or tumor that is produced due to excess cortisol by adrenal glands are the two basic factors that cause Cushing’s syndrome. Other tumors may also cause this disease, which are associated with inherited disorders such as multiple endocrine neoplasia type 1 and Carney complex. Most cases can be treated and cured by combination of surgery radiation or chemotherapy.

Download the PDF brochure:

The most significant cause of Cushing’s syndrome is intake of glucocorticoids prescribed by a healthcare professional to cure other diseases such as asthma, rheumatoid arthritis or in immunosuppression after an organ transplant. Administration of synthetic ACTH can also lead to the condition. It may also occur in other animals such as cats, dogs, and horse. All the factors mentioned above are expected to favor the growth of Cushing’s syndrome market.

Rise in cortisol hormone fuels the growth of Cushing’s syndrome market

Hormonal disorder caused due to prolonged exposure of body’s tissue to high levels of hormone cortisol leads to Cushing’s syndrome, also called hypercortisolism. Adults aged in the age group of 20-50 years suffer from Cushing’s syndrome. It is rarely seen, though has risk of development in patient who are obese and also have type 2 diabetes, high blood pressure with poorly controlled blood glucose.

Cushing’s syndrome market is projected to increase due to rise in its awareness and healthcare expenditure. Various new drugs are available in market due to increase in research and development such as ketoconazole, metyrapone and mitotane to minimize the surgical risk of patient. According to Orphanet Journal of Rare Disease, incidence of Cushing’s syndrome is estimated to be equal to 1–3 cases per million inhabitants per year, whereas its prevalence is close to 40 cases per million inhabitants in 2012.

Regional growth engines that supports Cushing’s syndrome market

According to Centers for Disease Control and Prevention more than one-third of the U.S. adults have obesity which is a leading cause to Cushing’s syndrome that was 36.5% during 2011-2014. Furthermore, according to American Diabetes Association type 2 diabetes is most commonly seen in African Americans, Latin Americans and Asia Pacific Islanders.

The key players dominating the global Cushing’s syndrome market

Increase in research and development in 2016, which includes development of clinical trials for RECORLEV for the treatment of endogenous Cushing’s syndrome by Strongbrigde Biopharma plc is expected to create competition and also favor the growth between various manufacture to lead the market. The key players operating in Cushing’s syndrome market include Corcept Therapeutics Inc., HRA Pharma, Strongbridge Biopharma plc. and Novartis AG. Click To Read More On Cushings Syndrome Market


About Author

Aira Goldsmith is a graduate of Parsons School of Design. She’s based in NYC but travels much of the year. Aira has written for Buzz Feed, Motherboard, The Financial Post, and the Huffington Post. Aira is a business reporter, focusing on technology and markets.